\u2212<\/b><\/sup>Findings of the survey are being presented at the virtual Congress of the European Crohn\u2019s and Colitis Organisation (ECCO) taking place on 2nd<\/sup> \u2013 3rd<\/sup> and 8th<\/sup> \u2013 10th<\/sup> July, 2021<\/i><\/b>1<\/sup><\/b><\/p>\n ZURICH & BRUSSELS–(BUSINESS WIRE<\/a>)– This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20210709005192\/en\/<\/a><\/p>\n \nThe survey found that CD patients living with perianal fistulas reported a more significant impact on their overall quality of life and an increase in certain symptoms, such as anal pain and perianal leaking, when compared to CD patients without perianal fistulas.1<\/sup> CD patients living with perianal fistulas also reported feeling more unhygienic, uncomfortable, and guilty about their condition toward family and friends than CD patients without perianal fistulas.1<\/sup><\/p>\n \nPerianal fistulas are a severe and disabling complication of Crohn\u2019s disease,7<\/sup> a chronic inflammatory disease that mainly affects the gastrointestinal tract and is associated with a substantial burden on the health-related quality of life of patients.8,9<\/sup> In adult patients with CD, the cumulative incidence of perianal fistulas is estimated to be 15%, 21-23% and 26-28% over five, 10 and 20 years, respectively.10,11,12 <\/sup>Despite this, there have been few studies assessing the patient perspective of living with the condition.1<\/sup><\/p>\n \nTo understand the burden across many aspects of life, the survey explored topics across many areas. The findings show that as well as impacting work and social life, perianal fistulas had a greater negative impact on CD patients\u2019 ability to do sports, work and employment, dating and sexual life.1<\/sup> 37.4% of CD patients with perianal fistulas stated that they were often unable to play sports, compared to 25.7% of CD patients without perianal fistulas.1<\/sup> When asked about sexual activity, 26.4% of CD patients with perianal fistulas avoided having sex, 6.9% have ended relationships and 5.5% have avoided dating because of their painful condition.1<\/sup> Almost double the number of CD patients with perianal fistulas compared to CD patients without perianal fistulas (14.3% vs. 8.0%) admitted they have had to change profession because of their condition.1<\/sup> On top of this, the survey revealed that CD patients with perianal fistulas found it more difficult to talk about their condition with others, impacting their relationships.1<\/sup><\/p>\n \n\u201cWe are proud to have embarked on this research to find out the impact of perianal fistulas on quality of life from patients\u2019 perspective,\u201d commented Luisa Avedano, Chief Executive Officer of EFCCA. \u201cThe results support what we have long suspected: that the added burden of perianal fistulas significantly impacts the lives of people with Crohn\u2019s disease. The results will help us work to empower Crohn\u2019s disease patients living with perianal fistulas and ultimately help to improve their lives.\u201d\n<\/p>\n \n\u201cWe conducted this survey in order to obtain this greater understanding of the burden of living with perianal fistulas in addition to Crohn\u2019s disease,\u201d said Dana Agam, Patient Advocacy and Services Lead, GI Franchise Takeda Europe and Canada. \u201cThe findings of this survey may be useful in helping to tailor comprehensive care strategies to better support patients with this painful and disabling complication.\u201d\n<\/p>\n \n###\n<\/p>\n About the International Patient Survey \nThe survey was commissioned and developed by EFCCA. Takeda provided editorial support in the development and distribution of the survey and analysis of data, and funded medical writing of the publication of results. The full survey findings are being presented at the virtual Congress of the European Crohn\u2019s and Colitis Organisation (ECCO) taking place on 2nd<\/sup> \u2013 3rd<\/sup> and 8th<\/sup> \u2013 10th<\/sup> July, 2021.1<\/sup><\/p>\n About Perianal Fistulas in CD European Federation of Crohn\u2019s and Ulcerative Colitis Associations (EFCCA) Takeda in Gastroenterology About Takeda Pharmaceutical Company Limited References<\/b><\/p>\n \n1\n<\/p>\n<\/td>\n \nSpinelli A, Yanai H, L\u00f6nnfors S, et al<\/i>. The impact of perianal fistula in Crohn\u2019s disease on quality of life: results of a patient survey conducted in Europe. Presented virtually at ECCO, July 2021.\n<\/p>\n<\/td>\n<\/tr>\n \n2\n<\/p>\n<\/td>\n \nSpinelli A, L\u00f6nnfors S, Avedano L, et al.<\/i> Patient perspective on the impact of complex perianal fistulas in Crohn\u2019s disease on quality of life: Introducing the concept of the patient survey conducted in Europe. Poster P042 presented at ECCO 2020.\n<\/p>\n<\/td>\n<\/tr>\n \n3\n<\/p>\n<\/td>\n \nPanes J, Reinisch W, Rupniewska E, et al.<\/i> Burden and outcomes for complex perianal fistulas in Crohn\u2019s disease: Systematic review. World J Gastroenterol. <\/i>2018; 24 (42) 4821 \u2013 4834.\n<\/p>\n<\/td>\n<\/tr>\n \n4\n<\/p>\n<\/td>\n \nKasparek M, Glatzle J, Temeltcheva T, et al.<\/i> Long-term quality of life in patients with Crohn\u2019s disease and perianal fistulas: Influencer of Fecal Diversion. Diseases of Colon and Rectum. <\/i>2007; 50: 2067 \u2013 2074.\n<\/p>\n<\/td>\n<\/tr>\n \n5\n<\/p>\n<\/td>\n \nMahadev S, Young J, Selby W, et al<\/i>. Quality of Life in Perianal Crohn\u2019s disease: What do patients consider important? Diseases of Colon and Rectum. <\/i>2011; 54 (5): 579 \u2013 585.\n<\/p>\n<\/td>\n<\/tr>\n \n6\n<\/p>\n<\/td>\n \nAdegbola S, Dibley L, Sahnan K, et al.<\/i> Burden of disease and adaptation to life in patients with Crohn\u2019s perianal fistula: a qualitative exploration. Health Qual Life Outcomes. <\/i>2020; 18: 370.\n<\/p>\n<\/td>\n<\/tr>\n \n7\n<\/p>\n<\/td>\n \nMarzo M, Felice C, Pugliese D, et al.<\/i> Management of perianal fistulas in Crohn\u2019s disease: An up-to-date review. World J Gastroenterol.<\/i> 2015; 21(5): 1394-1395.\n<\/p>\n<\/td>\n<\/tr>\n \n8\n<\/p>\n<\/td>\n \nFakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res.<\/i> 2014 Jun 23;7:113-120.\n<\/p>\n<\/td>\n<\/tr>\n \n9\n<\/p>\n<\/td>\n \nFloyd, D.N., Langham, S., S\u00e9verac, H.C. et al.<\/i> The Economic and Quality-of-Life Burden of Crohn\u2019s Disease in Europe and the United States, 2000 to 2013: A Systematic Review. Dig Dis Sci<\/i>. 2015; 60: 299\u2013312.\n<\/p>\n<\/td>\n<\/tr>\n \n10\n<\/p>\n<\/td>\n \nHellers G, Bergstrand O, Ewerth S and Holmstr\u04e7m B. Occurrence and outcome after primary treatment of anal fistulae in Crohn\u2019s disease. Gut<\/i> 1980; 21: 525-527.\n<\/p>\n<\/td>\n<\/tr>\n \n11\n<\/p>\n<\/td>\n \nSchwartz D, Loftus E, Tremaine W, et al<\/i>. The Natural History of Fistulizing Crohn\u2019s Disease in Olmsted County, Minnesota. Gastroenterology<\/i> 2002;122:875-880.\n<\/p>\n<\/td>\n<\/tr>\n \n12\n<\/p>\n<\/td>\n \nEglinton TW, Barclay ML, Gearry RB, et al.<\/i> The spectrum of perianal Crohn\u2019s disease in a population based cohort. Dis Colon Rectum. <\/i>2012; 55(7): 773-7.\n<\/p>\n<\/td>\n<\/tr>\n \n13\n<\/p>\n<\/td>\n \nXavier RJ and Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature<\/i>. 2007; 448: 427-434.\n<\/p>\n<\/td>\n<\/tr>\n \n14\n<\/p>\n<\/td>\n \nAguilera-Castro L, Ferre-Aracil C, Garcia-Garcia-de-Paredes A, et al<\/i>. Management of complex perianal Crohn\u2019s disease. Ann Gastroenterol.<\/i> 2017; 30: 33-44.\n<\/p>\n<\/td>\n<\/tr>\n \n15\n<\/p>\n<\/td>\n \nSandborn W, Fazio V, Feagan B, Hanauer S. AGA Technical review on perianal Crohn\u2019s disease. Gastroenterology. <\/i>2003; 125 (5): 1508-1530.\n<\/p>\n<\/td>\n<\/tr>\n \n16\n<\/p>\n<\/td>\n \nTorkzad MR and Karlbom U. MRI for assessment of anal fistula. Insights Imaging<\/i>. 2010; 1 (2) :62-71.\n<\/p>\n<\/td>\n<\/tr>\n \n17\n<\/p>\n<\/td>\n \nCenter for Drug Evaluation and Research (CDER) & the FDA. The Voice of the patient\/functional gastrointestinal disorder. 2016. Available at: https:\/\/www.fda.gov\/media\/95140\/download<\/a>. Last accessed July 2021.\n<\/p>\n<\/td>\n<\/tr>\n \n18\n<\/p>\n<\/td>\n \nJones R, Hunt C, Stevens R, et al.<\/i> Management of common gastrointestinal disorders: quality criteria based on patients\u2019 views and practice guidelines. Br J Gen Pract<\/i>. 2009; 59: e199-208.\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \nCopyright 2021 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited.\n<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210709005192\/en\/<\/a><\/span><\/p>\n Media Contacts: Takeda KEYWORDS:<\/b> Belgium Europe Switzerland<\/p>\n INDUSTRY KEYWORDS:<\/b> Biotechnology Health Science Pharmaceutical Research<\/p>\n
\nThe European Federation of Crohn\u2019s and Ulcerative Colitis Associations<\/a>(\u201cEFCCA\u201d)<\/b> in collaboration with Takeda Pharmaceutical Company Limited<\/a>(\u201cTakeda\u201d) <\/b>today announced results from one of the largest of its kind self-reported patient surveys, exploring the health-related and overall real-world impact of perianal fistulas on the quality of life of people with Crohn\u2019s disease (CD), compared to the impact of CD without perianal fistulas.1,2,3,4,5,6<\/sup><\/p>\n
\n
<\/b>There were 820 respondents to the anonymous, self-selective survey,1<\/sup> making it one of the most comprehensive surveys on the patient perspective on life with perianal fistulas in Crohn\u2019s disease to date.1,2,3,4,5,6<\/sup> To ensure the results would provide valuable insights, the questionnaire was developed in cooperation with both medical and patient representatives.1<\/sup> It consisted of 46 questions and assessed multiple aspects of living with CD, including topics such as impact on close relationships and social life, and impact on professional life.2<\/sup> The survey itself which invited CD patients, with or without perianal fistulas to participate and self-select their diagnosis, was available through the EFCCA website from 15th<\/sup> July to 31st<\/sup> December 2019.1<\/sup> Responses were received from 33 countries around the world, including countries in Europe, Colombia, Israel, Mexico, United States, Greenland, Dominican Republic and Guadeloupe.2<\/sup> It was made available in English, French, German, Greek, Hebrew, Italian, Polish, Portuguese, Romanian, Spanish and Slovenian.2<\/sup><\/p>\n
\n
<\/b>CD is a chronic inflammatory disease of the digestive system.13<\/sup> People living with CD may experience perianal fistulas, which can cause intense pain, swelling, infection, and anal discharge.7,14<\/sup> In adult patients with CD, the cumulative incidence of perianal fistulas is estimated to be 15%, 21-23% and 26-28% over five, 10 and 20 years, respectively.10,11,12 <\/sup>Perianal fistulas in CD are abnormal tracts with an internal opening in the anal canal or rectum and an external opening in the skin near the anus.15,16 <\/sup>They may develop from inflamed or infected anal glands and\/or penetration of fissures or ulcers in the rectum or anal canal.15,16<\/sup><\/p>\n
\n
<\/b>The European Federation of Crohn\u2019s and Ulcerative Colitis Associations (EFCCA) is an umbrella organization representing 45 national Crohn\u2019s disease and ulcerative colitis (collectively known as inflammatory bowel disease or IBD) patient associations. We are an organization of people united in our commitment to improve the lives of the over 10 million people living with IBD worldwide (3.4 million in Europe alone) and to give them a louder voice and more visibility. Our areas of intervention are networking, awareness raising, advocacy, empowerment, and solidarity. Our mission is to improve the lives of people with Crohn\u2019s disease and ulcerative colitis. Our vision and ultimate goal are to find a cure for IBD.\n<\/p>\n
\n
<\/b>We believe that gastrointestinal (GI) and liver diseases are not just life-disrupting conditions, but diseases that can impact a patient\u2019s quality of life.17,18 <\/sup>Beyond a fundamental need for effective treatment options, we understand that improving patients\u2019 lives also depends on their needs being recognized. With nearly 30 years of experience in gastroenterology, Takeda has made significant strides in addressing GI patient needs with treatments for inflammatory bowel disease (IBD), acid-related diseases, short bowel syndrome (SBS), and motility disorders. We are making significant strides toward closing the gap on new areas of unmet needs for patients who have celiac disease, eosinophilic esophagitis, alpha-1 antitrypsin-associated liver disease, and acute pancreatitis, among others. Together with researchers, patient groups and more, we are working to advance scientific research and clinical medicine in GI.\n<\/p>\n
\n
<\/b>Takeda Pharmaceutical Company Limited (TSE: 4502\/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people\u2019s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in healthcare in approximately 80 countries. For more information, visit https:\/\/www.takeda.com\/<\/a>.\n<\/p>\n
\n\n
\n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n \n \n \u00a0<\/td>\n \n <\/p>\n
\n<\/b>
EFCCA
\n
Isabella Haaf
\n
Bella.haaf@efcca.org
\n<\/a>
+32 2 540 84 34<\/p>\n
\n
Luke Willats
\n
luke.willats@takeda.com
\n<\/a>
+41-44-555-1145\n<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20210709005192\/en\/889900\/3\/EFCCA_logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20210709005192\/en\/889901\/3\/Takeda_Logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n